| Literature DB >> 26865327 |
Jie Liu1, Shang Wei Zuo1, Yue Li1, Xin Jia1, Sen Hao Jia1, Tao Zhang2, Yu Xiang Song1, Ying Qi Wei3, Jiang Xiong1, Yong Hua Hu3, Wei Guo1.
Abstract
The associations between hyperhomocysteinaemia (HHcy), methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, and abdominal aortic aneurysm (AAA) remain controversial, with only few studies focused on these associations within the Chinese population. We performed subgroup and interaction analyses in a Chinese Han population to investigate these associations. In all, 155 AAA patients and 310 control subjects were evaluated for serum total homocysteine levels and MTHFR C677T polymorphisms. Multiple logistic regression models were used to evaluate the aforementioned associations. Interaction and stratified analyses were conducted according to age, sex, smoking status, drinking status, and chronic disease histories. The multiple logistic analyses showed a significant association between HHcy and AAA but no significant association between MTHFR C677T polymorphism and AAA. The interaction analysis showed that age and peripheral arterial disease played an interactive role in the association between HHcy and AAA, while drinking status played an interactive role in the association between MTHFR C677T polymorphism and AAA. In conclusion, HHcy is an independent risk factor of AAA in a Chinese Han population, especially in the elderly and peripheral arterial disease subgroups. Longitudinal studies and clinical trials aimed to reduce homocysteine levels are warranted to assess the causal nature of these relationships.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26865327 PMCID: PMC4750057 DOI: 10.1038/srep17966
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographic characteristics of the abdominal aortic aneurysm (AAA) group and the control groups.
| Control groups (n = 310) | |||||
|---|---|---|---|---|---|
| Variable | AAA group (n = 155) | Control group 1 (n = 155) | Control group 2 (n = 155) | P 1 values | P 2 values |
| Age, years | 69.18 ± 9.94 | 69.59 ± 10.86 | 69.45 ± 8.95 | 0.89 | 0.85 |
| Sex, male | 138 (89.0) | 138 (89.0) | 138 (89.0) | 1.00 | 1.00 |
| Smoking habits | 132 (85.2) | 69 (44.5) | 98 (63.2) | <0.01 | <0.01 |
| Drinking habits | 79 (51.0) | 58 (37.4) | 67 (43.2) | 0.30 | 0.03 |
| SBP | 130.60 ± 17.32 | 136.70 ± 17.78 | 137.53 ± 21.04 | 0.59 | 0.003 |
| DBP | 78.66 ± 10.71 | 80.22 ± 10.40 | 87.07 ± 12.73 | <0.001 | <0.001 |
| Hypertension | 108 (69.7) | 64 (41.3) | 79 (51.0) | 0.09 | <0.001 |
| Dyslipidaemia | 118 (76.1) | 65 (41.9) | 73 (47.1) | 0.36 | <0.01 |
| Type 2 diabetes | 18 (11.6) | 27 (17.4) | 19 (12.3) | 0.20 | 0.34 |
| CAD | 53 (34.2) | 36 (23.2) | 44 (28.4) | 0.30 | 0.06 |
| Ischemic stroke | 29 (18.7) | 17 (11.0) | 14 (9.0) | 0.57 | 0.01 |
| PAD | 51 (32.9) | 22 (14.2) | 29 (18.7) | 0.28 | <0.01 |
| Aorta diameter, mm | 52.00(44.00-61.00) | 17.00(15.40-20.00) | 16.10(14.62-17.70) | 0.10 | <0.001 |
| tHcy, μmol/l | 22.21 ± 13.10 | 18.37 ± 9.61 | 18.60 ± 11.32 | 0.10 | <0.001 |
CAD, Coronary artery disease; PAD, peripheral arterial disease; tHcy, serum total homocysteine.
Continuous data are shown as the mean ± standard deviation or median (lower quantile, upper quantile), and categorical data as number (%).
P1 values were calculated by comparing demographic or clinical characteristics between two control groups and P2 values were calculated by comparing characteristics between AAA and all controls.
Figure 1Distribution of serum total homocysteine levels in patients with AAA and control subjects.
Serum homocysteine levels of different C677T MTHFR genotype in the abdominal aortic aneurysm (AAA) group and the control groups.
| Homocysteine (μmol/L) | ||
|---|---|---|
| AAA group | CC | 14.70 ± 6.58 |
| CT | 20.98 ± 10.93* | |
| TT | 28.88 ± 16.07** | |
| Control groups | CC | 14.56 ± 6.99 |
| CT | 15.79 ± 7.72 | |
| TT | 23.43 ± 12.50** |
*CT vs CC: p < .05; **TT vs CT and TT vs CC: p < .05.
Multinomial logistic regression models evaluating the association of serum total homocysteine (tHcy) with abdominal aortic aneurysm (AAA).
| Variable | Crude | P | Adjusted | P |
|---|---|---|---|---|
| OR, 95% CI | OR, 95% CI | |||
| Hcy, 1 μmol/L | 1.03 (1.01, 1.04) | <0.001 | 1.02 (1.00, 1.05) | 0.03 |
| Hcy < 15 μmol/L | Ref | — | Ref | — |
| Hcy ≥ 15 μmol/L | 2.97 (1.94, 4.55) | <0.001 | 2.84 (1.63, 4.93) | <0.001 |
aAdjusted for age, sex, smoking status, drinking status, hypertension, dyslipidaemia, type 2 diabetes, coronary artery disease (CAD), ischemic stroke, and peripheral arterial disease (PAD).
CI, confidence interval; OR, odds ratio.
Association between hyperhomocystenaemia (HHcy) and abdominal aortic aneurysm (AAA) according to baseline characteristics.
| Subgroup | AAA group(n) | Control groups(n) | OR, 95% CI | P Value | P Value forInteraction | ||
|---|---|---|---|---|---|---|---|
| HHcy | nHcy | HHcy | nHcy | ||||
| Age | 0.016 | ||||||
| <70 yr | 42 | 26 | 67 | 74 | 1.78 (0.99, 3.22) | 0.06 | |
| ≥ 70 yr | 74 | 13 | 88 | 81 | 5.24 (2.70, 10.16) | <0.001 | |
| Sex | 0.65 | ||||||
| Male | 107 | 31 | 144 | 132 | 3.16 (1.99, 5.03) | <0.001 | |
| Female | 9 | 8 | 11 | 23 | 2.35 (0.713, 7.76) | 0.160 | |
| Smoking Habits | 0.20 | ||||||
| No | 13 | 10 | 65 | 78 | 1.56 (0.642, 3.79) | 0.326 | |
| Yes | 103 | 29 | 90 | 77 | 3.04 (1.82, 5.07) | <0.001 | |
| Drinking Habits | 0.51 | ||||||
| No | 55 | 21 | 93 | 92 | 2.59 (1.45, 4.63) | 0.001 | |
| Yes | 61 | 18 | 62 | 63 | 3.44 (1.83, 6.48) | <0.001 | |
| Hypertension | 0.92 | ||||||
| No | 35 | 12 | 82 | 85 | 3.02 (1.47, 6.23) | 0.003 | |
| Yes | 81 | 27 | 73 | 70 | 2.88 (1.67, 4.96) | <0.001 | |
| Dyslipidaemia | 0.88 | ||||||
| No | 60 | 19 | 125 | 124 | 3.13 (1.77, 5.55) | <0.001 | |
| Yes | 56 | 20 | 30 | 31 | 2.89 (1.41, 5.92) | 0.004 | |
| Type 2 diabetes | 0.66 | ||||||
| No | 104 | 33 | 139 | 125 | 2.83 (1.79, 4.49) | <0.001 | |
| Yes | 12 | 6 | 16 | 30 | 3.75 (1.18, 11.87) | 0.025 | |
| CAD | 0.49 | ||||||
| No | 76 | 26 | 119 | 111 | 2.73 (1.63, 4.56) | <0.001 | |
| Yes | 40 | 13 | 36 | 44 | 3.76 (1.75, 8.08) | <0.001 | |
| Ischemic stroke | 0.74 | ||||||
| No | 92 | 34 | 137 | 142 | 2.80 (1.77, 4.43) | <0.001 | |
| Yes | 24 | 5 | 18 | 13 | 3.47 (1.05, 11.50) | 0.042 | |
| PAD | 0.01 | ||||||
| No | 72 | 32 | 133 | 126 | 2.13 (1.32, 3.45) | 0.002 | |
| Yes | 44 | 7 | 22 | 29 | 8.29 (3.14, 21.88) | <0.001 | |
| MTHFR genotype | 0.94 | ||||||
| CC/CT | 74 | 33 | 74 | 116 | 3.52 (2.12, 5.81) | <0.001 | |
| TT | 42 | 6 | 81 | 39 | 3.37 (1.32, 8.60) | 0.011 | |
OR, odds ratio; CI, confidence interval.
CAD, Coronary artery disease; PAD, peripheral arterial disease; nHcy, normal serum homocysteine level; MTHFR, methylenetetrahydrofolate reductase.
Figure 2Odds ratios for abdominal aortic aneurysm, according to baseline characteristics.
Allele and genotype frequencies of MTHFR C677T polymorphism in patients and controls.
| C677T MTHFR Genotype | AAA, No. (%) | Control, No. (%) | Crude | P | Adjusted | P |
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||||
| CC | 30 (19.4) | 65 (21.0) | 1.0 (referent) | — | 1.0 (referent) | — |
| CT | 77 (49.7) | 125 (40.3) | 1.33 (0.80, 2.24) | 0.27 | 0.95 (0.496, 1.83) | 0.88 |
| TT | 48 (31.0) | 120 (38.7) | 0.87 (0.50, 1.50) | 0.61 | 0.72 (0.36, 1.42) | 0.34 |
| TT/CT | 125 (80.6) | 245 (79.0) | 1.11 (0.68, 1.79) | 0.68 | 0.84 (0.46, 1.54) | 0.57 |
aAdjusted for age, sex, smoking status, drinking status, hypertension, dyslipidaemia, type 2 diabetes, coronary artery disease (CAD), ischemic stroke, and peripheral arterial disease (PAD).
CI, Confidence interval; OR, odds ratio; MTHFR, methylenetetrahydrofolate reductase.
Association between C677T MTHFR genotype and AAA according to baseline characteristics.
| Subgroup | AAA group (n) | Control groups (n) | CC | OR, 95% CI | P Value | P Value for Interaction | |
|---|---|---|---|---|---|---|---|
| TT/CT | CC | TT/CT | |||||
| Age | 0.06 | ||||||
| <70 yr | 50 | 18 | 113 | 28 | 0.69 (0.35, 1.36) | 0.28 | |
| ≥70 yr | 75 | 12 | 132 | 37 | 1.75 (0.86, 3.56) | 0.12 | |
| Sex | 0.08 | ||||||
| Male | 113 | 25 | 215 | 61 | 1.28 (0.76, 2.15) | 0.35 | |
| Female | 12 | 5 | 30 | 4 | 0.32 (0.073, 1.40) | 0.13 | |
| Smoking Habits | 0.12 | ||||||
| No | 15 | 8 | 112 | 31 | 0.52 (0.20, 1.34) | 0.17 | |
| Yes | 110 | 22 | 133 | 34 | 1.28 (0.71, 2.31) | 0.42 | |
| Drinking Habits | 0.006 | ||||||
| No | 55 | 21 | 150 | 35 | 0.61 (0.33, 1.14) | 0.12 | |
| Yes | 70 | 9 | 95 | 30 | 2.46 (1.10, 5.50) | 0.03 | |
| Hypertension | 0.11 | ||||||
| No | 36 | 11 | 138 | 29 | 0.69 (0.31, 1.51) | 0.35 | |
| Yes | 89 | 19 | 107 | 36 | 1.58 (0.85, 2.94) | 0.15 | |
| Dyslipidaemia | 0.23 | ||||||
| No | 60 | 19 | 197 | 52 | 0.83 (0.46, 1.52) | 0.55 | |
| Yes | 65 | 11 | 48 | 13 | 1.60 (0.66, 3.88) | 0.30 | |
| Type 2 diabetes | 0.46 | ||||||
| No | 109 | 28 | 208 | 56 | 1.05 (0.63, 1.74) | 0.86 | |
| Yes | 16 | 2 | 37 | 9 | 1.95 (0.38, 10.04) | 0.43 | |
| CAD | 0.60 | ||||||
| No | 81 | 21 | 177 | 53 | 1.15 (0.65, 2.04) | 0.62 | |
| Yes | 44 | 9 | 68 | 12 | 0.86 (0.34, 2.22) | 0.76 | |
| Ischemic stroke | 0.93 | ||||||
| No | 101 | 25 | 220 | 59 | 1.08 (0.64, 1.83) | 0.76 | |
| Yes | 24 | 5 | 25 | 6 | 1.15 (0.31, 4.28) | 0.83 | |
| PAD | 0.46 | ||||||
| No | 84 | 20 | 208 | 51 | 1.03 (0.58, 1.83) | 0.92 | |
| Yes | 41 | 10 | 37 | 14 | 1.55 (0.62, 3.91) | 0.35 | |
| Hcy | 0.19 | ||||||
| HHcy | 101 | 15 | 132 | 23 | 1.17 (0.58, 2.36) | 0.66 | |
| nHcy | 24 | 15 | 113 | 42 | 0.60 (0.29, 1.24) | 0.17 | |
CI, confidence interval; OR, odds ratio.
MTHFR, methylenetetrahydrofolate reductase; CAD, coronary artery disease; PAD, peripheral arterial disease; HHcy, hyperhomocysteinaemia ; nHcy, normal serum homocysteine level.